Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is an exciting biopharmaceutical company that is utilizing innovative technologies to develop potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. With its promising product candidates, vilobelimab and izicopan, the company is targeting a wide range of inflammatory and autoimmune diseases. In particular, the potential for izicopan to effectively replace the now impaired Tavneos (avacopan) as non-steroidal standard-of-care in ANCA-associated vasculitis (AAV) gives a positive outlook on the company's future. Additionally, the company's plans for PK bridging studies in China, open-label studies in other locations, and exploring the potential of izicopan in inflammatory renal diseases demonstrate potentially strong growth opportunities. Although there are risks, including potential competition and FDA approval challenges, we remain Overweight on IFRX and have increased our price target to $8 based on our updated financial model and its promising clinical focus.

Bears say

InflaRx is facing potential clinical and competitive risks with its product candidate, Izicopan, with Phase 3 trial endpoints focused on efficacy and the need for successful trials in renal diseases. In addition, the company faces the possibility of failure in CSU and HS and subsequent need to pivot to other indications, with other potential treatments being increasingly competitive. The potential setbacks could have a significant impact on the company's future success and financial stability.

InflaRx (IFRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 5 analysts, InflaRx (IFRX) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.